The AAV Vector Challenge With Selecta's Dr. Carsten Brunn
The Business of Biotech kicks off our Cell a Gene Miniseries with Dr. Carsten Brunn, President a CEO at Selecta Biosciences. Guest host Erin Harris, chief editor at cellandgene.com, joins us for a discussion on Selecta's ImmTOR platform and how the company is addressing the immunogenicity of adeno-associated virus (AAV) vectors challenge faced by gene therapy companies.
